US stock · Healthcare sector · Biotechnology
Company Logo

Rigel Pharmaceuticals, Inc.

RIGLNASDAQ

1.10

USD
-0.06
(-5.17%)
Market Closed
-2.24P/E
-4Forward P/E
-0.11P/E to S&P500
190.120MMarket CAP
- -Div Yield
Upcoming Earnings
31 Oct-4 Nov
Shares Short
8/31/22
9.42M
Short % of Float
6.40%
Short % of Shares Outs.
5.45%
% Held by Insiders
1.20%
% Held by Institutions
88.40%
Beta
1.54
PEG Ratio
-0.03
52w. high/low
3.81/0.64
Avg. Daily Volume
4.11M
Return %
Stock
S&P 500
1 year
(71.28)
(16.94)
3 years
(34.91)
24.30
5 years
(52.59)
48.01
Scale: |
High
Low
31.00
6.64
29.25
4.76
14.75
4.19
10.03
6.02
10.21
6.42
11.44
5.37
7.61
2.31
5.00
1.56
5.20
2.02
4.38
1.88
4.47
1.94
4.71
1.96
2.69
1.56
5.24
1.23
5.50
2.30
3.52
0.64
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
1.34
0.44
- -
0.02
2.40
0.08
0.03
0.08
0.09
0.33
0.22
0.04
0.28
0.35
0.64
0.88
0.52
Earnings per share
(1.51)
(2.57)
(3.67)
(2.73)
0.73
(1.36)
(1.32)
(1.02)
(1.04)
(0.58)
(0.73)
(0.62)
(0.44)
(0.40)
(0.18)
(0.11)
(0.49)
FCF per share
(1.47)
(1.84)
(2.94)
(2.52)
0.83
(1.13)
(1.18)
(1.00)
(0.80)
(0.27)
(0.81)
(0.62)
(0.37)
(0.26)
(0.32)
0.03
(0.40)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.04
0.03
0.07
0.00
0.07
0.04
0.05
0.01
0.00
0.01
0.01
0.00
0.01
0.01
0.01
0.00
0.00
Book Value per sh.
3.50
2.84
2.89
2.69
3.19
3.73
3.86
2.39
1.46
1.03
0.58
0.80
0.68
0.32
0.20
0.18
0.12
Comm.Shares outs.
25
29
36
41
52
63
75
87
88
88
94
126
161
167
169
169
171
Avg. annual P/E ratio
(6.7)
(4.2)
(5.3)
(2.9)
11.0
(5.7)
(6.8)
(4.5)
(2.8)
(5.5)
(3.7)
(4.7)
(7.7)
(5.5)
(13.9)
(34.9)
(2.2)
P/E to S&P500
(0.4)
(0.2)
(0.2)
(0.0)
0.5
(0.4)
(0.5)
(0.3)
(0.2)
(0.3)
(0.2)
(0.2)
(0.3)
(0.2)
(0.4)
(1.2)
(0.1)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
33
13
- -
1
125
5
2
7
8
29
20
4
45
59
109
149
89
Operating margin
(128.6)%
(631.2)%
(Infinity)%
(14,938.3)%
28.3%
(1,818.3)%
(4,416.8)%
(1,251.3)%
(1,106.0)%
(179.1)%
(342.2)%
(1,775.6)%
(163.3)%
(116.5)%
(26.7)%
(8.4)%
(99.3)%
Depreciation (m)
1
1
1
1
1
2
2
3
2
1
1
0
1
1
1
1
1
Net profit (m)
(38)
(74)
(132)
(112)
38
(86)
(99)
(89)
(91)
(51)
(69)
(78)
(70)
(67)
(30)
(18)
(85)
Income tax rate
- -
- -
0.1%
0.1%
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(3.5)%
0.2%
Net profit margin
(112.4)%
(589.5)%
(Infinity)%
(14,872.9)%
30.3%
(1,810.0)%
(4,392.9)%
(1,245.1)%
(1,101.9)%
(178.1)%
(339.6)%
(1,739.3)%
(158.3)%
(112.8)%
(27.4)%
(12.0)%
(104.4)%
Working capital (m)
97
95
114
118
169
239
290
210
137
95
54
99
109
61
48
91
66
Long-term debt (m)
- -
- -
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
10
30
21
- -
Equity (m)
87
82
104
110
166
236
289
208
128
91
55
101
110
54
34
30
(4)
ROIC
- -
- -
(114.1)%
(90.5)%
21.7%
(35.0)%
(33.2)%
(41.3)%
(64.9)%
(52.5)%
(124.6)%
(77.4)%
(63.3)%
(74.5)%
(40.8)%
(12.4)%
(110.4)%
Return on capital
(33.0)%
(64.0)%
(95.0)%
(79.2)%
20.3%
(33.4)%
(31.9)%
(39.4)%
(59.0)%
(39.1)%
(88.6)%
(65.5)%
(50.7)%
(45.1)%
(25.7)%
(7.4)%
(63.0)%
Return on equity
(43.1)%
(90.4)%
(127.1)%
(101.5)%
22.8%
(36.4)%
(34.2)%
(42.7)%
(70.9)%
(56.3)%
(125.8)%
(77.5)%
(64.1)%
(124.3)%
(87.4)%
(59.0)%
2,298.9%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
(4.5)%
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
2 Aug · 2022 | Q2
All numbers in millions
Total liabilities
$ 131
Total assets
$ 128
Long-term debt
$ - -
Cash and equiv.
$ 27
Goodwill
$ - -
Retained earnings
$ (1,365)
Common stock
172
Enterprise Value
$ 163
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
98
57
125
Receivables
10
16
15
Inventory
1
2
7
Other
9
22
4
Current assets
119
89
154
Acc. Payable
4
4
4
Debt due
- -
9
10
Other
54
29
50
Current liabilities
58
41
64
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
37.39%
261.61%
158.04%
Cash flow
(109.82)%
(34.16)%
(0.23)%
Earnings
(39.77)%
(27.51)%
(12.67)%
Dividends
- -
- -
- -
Book value
(10.73)%
(22.34)%
(15.71)%
Insider Trading
Type
Shares
Date
Schorno Dean L
Award
81,250
09/14/22
Rodriguez Raul R
Award
300,000
09/14/22
Vance Dolly
Award
81,250
09/14/22
Rodriguez Raul R
Purchase
1,000,000
06/09/22
Kotzin Brian L.
Award
30,000
05/20/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
56
16
18
18
109
2021
81
26
22
20
149
2022
17
30
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.13
(0.10)
(0.08)
(0.11)
(0.18)
2021
0.23
(0.08)
(0.12)
(0.13)
(0.11)
2022
(0.16)
(0.08)
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Raul Rodriguez
Full-time employees:
165
City:
South San Francisco
Address:
1180 Veterans Blvd
IPO:
Nov 29, 2000
Website:
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Recent News